Source:http://linkedlifedata.com/resource/pubmed/id/20409372
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2010-4-22
|
| pubmed:abstractText |
In the Netherlands, the 7-valent pneumococcal conjugate vaccine (PCV-7) was implemented in a 3+1-dose schedule in the national immunization program for infants born after April 1, 2006. To assess the vaccine's effectiveness, we compared disease incidence before and after vaccine implementation (June 2004-June 2006 and June 2006-June 2008, respectively). We serotyped 2,552 invasive pneumococcal isolates from throughout the Netherlands, covering 25% of the country's population. Clinical characteristics were extracted from hospital records. After June 2006, vaccine-serotype invasive pneumococcal disease (IPD) decreased 90% (95% confidence interval [CI] 68%-97%) in children age eligible for PCV-7; simultaneously, however, non-vaccine-serotype IPD increased by 71% (not significant), resulting in a 44% total net IPD reduction (95% CI 7%-66%). IPD rates did not change for other age groups. In the Netherlands, PCV-7 offered high protection against vaccine-serotype IPD in vaccinated children, but increases of non-vaccine-serotype IPD reduced net vaccine benefits.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
1080-6059
|
| pubmed:author |
pubmed-author:HakEelkoE,
pubmed-author:JansenAngelique G C SAG,
pubmed-author:RodenburgGerwin DGD,
pubmed-author:SandersElisabeth A MEA,
pubmed-author:SchoulsLeo MLM,
pubmed-author:SpanjaardLodewijkL,
pubmed-author:de GreeffSabine CSC,
pubmed-author:de MelkerHester EHE,
pubmed-author:van der EndeArieA
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
16
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
816-23
|
| pubmed:dateRevised |
2010-10-21
|
| pubmed:meshHeading |
pubmed-meshheading:20409372-Adolescent,
pubmed-meshheading:20409372-Adult,
pubmed-meshheading:20409372-Age Factors,
pubmed-meshheading:20409372-Aged,
pubmed-meshheading:20409372-Child,
pubmed-meshheading:20409372-Child, Preschool,
pubmed-meshheading:20409372-Humans,
pubmed-meshheading:20409372-Incidence,
pubmed-meshheading:20409372-Infant,
pubmed-meshheading:20409372-Middle Aged,
pubmed-meshheading:20409372-Netherlands,
pubmed-meshheading:20409372-Pneumococcal Infections,
pubmed-meshheading:20409372-Pneumococcal Vaccines,
pubmed-meshheading:20409372-Population Surveillance,
pubmed-meshheading:20409372-Serotyping,
pubmed-meshheading:20409372-Streptococcus pneumoniae,
pubmed-meshheading:20409372-Time Factors,
pubmed-meshheading:20409372-Treatment Outcome
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands.
|
| pubmed:affiliation |
Wilhelmina Children's Hospital/University Medical Center, Utrecht, the Netherlands. g.d.rodenburg@umcutrecht.nl
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|